Goal

The Ototoxicity prevention program is evaluating oral and intravenous compounds in R&D for the prevention of drug-induced ototoxicity.

The focus of this program is to:

  • Reduce hearing loss induced by cisplatin toxicity
  • Avoid any interference with the use and effectiveness of cisplatin during chemotherapy

Cisplatin-induced Ototoxicity

Platinum-based agents such as cisplatin, carboplatin and oxaliplatin, alone or in combination, are often used to treat a wide variety of cancers. However, they have common and often severe adverse effects including:

  • Renal toxicity
  • Hematological or gastrointestinal trauma
  • Ototoxicity leading to hearing loss and tinnitus

Cisplatin specifically is used in 25% of primary chemotherapeutic treatment of various cancers. Hearing loss with cisplatin is:

  • Seen in more than 30% of adults
  • Observed to varying degrees in >70% of treated children
  • Progressive, worsening with each successive chemotherapy cycle
  • Irreversible

 

References:
Rybak et al., (2009) Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies. Tohoku J Exp Med. 219(3): 177–186. Pubmed

Latest news

  • 08 Jun 2017

    Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved Read

  • 08 Jun 2017

    Sensorion takes a key step towards phase 2 with SENS-401 thanks to the positive results obtained in the phase 1 clinical trial Read

Patient center

Corporate presentation